The activation of plasmacytoid dendritic cells (pDCs) can induce T-cell activation or tolerance; the NK CD56 bright cells can be used as antitumor effectors in cancer immunotherapies (Wagner et al., 2017). Here, NCAM1 is linked to cancer.